Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of SKYCovione (GBP510) vs ChAdOx1-S Vaccine for COVID-19
NCT05007951Phase 3Completed
- Sponsor
- SK bioscience
- Start
- Aug 2021
- Primary completion
- Oct 2023
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of GBP510 in coronavirus disease 2019 (COVID-19), sponsored by SK bioscience. Primary endpoints: Geometric Mean Titer of neutralizing antibody to SARS-CoV-2 (wild-type), Percentage of participants with >= 4-fold rise in wild-type virus neutralizing antibody titer and 1 more. Started Aug 2021; status: completed.
02
Drugs
GBP510
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05007951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007951.